and bebtelovimab.
Pursuant to EUAs or similar regulatory authorizations, we recognized net product revenue associated with our sales of our COVID-19 antibodies of $
2.02
billion during 2022. We had
no
sales of our COVID-19 antibodies during the years ended December 31, 2024 and 2023.
Divestitures
Olanzapine Portfolio (including Zyprexa)
In July 2023, we sold the rights for the olanzapine portfolio, including Zyprexa, to Cheplapharm Arzneimittel GmbH (Cheplapharm), a European company. Under the terms of the agreement, we received $
1.05
billion in cash in 2023 and an additional $
305.0
million in cash in 2024. We included both in the transaction price in 2023.
We entered into a supply agreement with Cheplapharm that obligates Cheplapharm to purchase Zyprexa product we are manufacturing at an amount which represents a standalone selling price. As the product we are manufacturing under this supply agreement has no alternative use to us and we have right to payment, we recognize net product revenue over time as we manufacture the product.
74
During the year ended December 31, 2023, we recognized $
1.45
billion in revenue primarily related to the net gain on the sale of rights for the olanzapine portfolio.
Baqsimi
In June 2023, we sold the rights for Baqsimi
to Amphastar Pharmaceuticals, Inc. (Amphastar). Under the terms of the agreement, we received $
500.0
million in cash in 2023 and an additional $
125.0
million in cash in 2024. We included both in the transaction price in 2023. We are eligible to receive payments of up to $
450.0
million in a series of sales-based milestones, that have not been included in the transaction price as of December 31, 2024.
We entered into a supply agreement with Amphastar that obligates Amphastar to purchase Baqsimi product we are manufacturing at an amount which represents a standalone selling price. As the product we are manufacturing under this supply agreement has no alternative use to us and we have right to payment, we recognize net product revenue over time as we manufacture the product.
During the year ended December 31, 2023, we recognized $
579.0
million in revenue primarily related to the net gain on the sale of rights for Baqsimi.
Note 5:
Asset Impairment, Restructuring, and Other Special Charges
Asset impairment, restructuring, and other special charges were $
860.6
million, $
67.7
million, and $
244.6
million for the years ended December 31, 2024, 2023, and 2022, respectively.
Asset impairment, restructuring, and other special charges
recognized during the year ended December 31, 2024 were primarily related to a $
435.0
million litigation charge and an intangible asset impairment for Vitrakvi, driven by expected commercial projections. See Note 16 for additional information related to the litigation charge.
Asset impairment, restructuring, and other special charges recognized during the year ended December 31, 2022 were primarily related to an intangible asset impairment driven by delays in estimated